India being a tropical country occupies No.1 slot for GI disorders and Respiratory disorders. Out of the total pharmaceutical market of 30,000 Cr, roughly 40 % market is attributed to these disorders. Child Birth and neglected Women's Healthcare attributes to the huge Gynaec segment and our presence in this segment being strong the growth promise is the highest. This being mass segment category big revenue is envisaged.

In October 2007 Mark Remedies further strengthened their presence in the domestic market by launching "Epigrof", which is path breaker in the treatment of burns and diabetic foot ulcers. We take pride in stating that we are the first to launch Epidermal Growth Factor with Silver Sulphadiazine in India with the brand name Epigrof.

Internationally this combination is available with the brand name Hebermin. We are getting our raw material from Cuba (The manufacturers of Hebermin) which is 95% pure and thus our product Epigrof assures quality equivalent to that of the international brand.

Epigrof is fast gaining acceptance among doctors and patient for the treatment of burns and diabetic foot ulcers and the results in the form of prescriptions and sales is overwhelming.

Our aim is to emerge as one of the major players in antibiotics segment and to cater to the Child Birth and Women's Healthcare need. Introduce new therapies in the segment of GI disorders and Respiratory disorders and thus enhance the quality of treatment provided to the patients in these two segments.

We are currently venturing into the segment of Dermatology which has huge market potential and thus make a huge impact in this market and gain the maximum out of it.